Market cap
₹166 Cr
Recently Viewed
Clear AllNSE: BROOKS | BSE: 533543
₹55.98
₹-2.88
(-4.89%)
As on 30-Apr-2026IST
Market cap
₹166 Cr
Revenue (TTM)
₹89 Cr
P/E Ratio
7.7
P/B Ratio
1.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹22 Cr
ROE
-12.2 %
ROCE
-10 %
Industry P/E
29.51
EV/EBITDA
18.5
Debt to Equity
0.1
Book Value
₹39.4
EPS
₹7.3
Face value
10
Shares outstanding
29,457,248
CFO
₹-57.58 Cr
EBITDA
₹-40.83 Cr
Net Profit
₹-139.99 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Brooks Lab
| -30.1 | 29.6 | -9.6 | -58.2 | -3.9 | -6.9 | -1.7 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Brooks Lab
| -56.4 | 23.4 | 32.6 | 8.9 | 43.9 | 170.4 | -51.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Brooks Lab
|
56.0 | 166.4 | 88.9 | 6.5 | 7.2 | 20.2 | 7.7 | 1.4 |
| 2,822.7 | 35,289.3 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.8 | 7.7 | |
| 8,213.0 | 20,543.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 102.3 | 24.7 | |
| 1,709.0 | 13,002.6 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.2 | 3.9 | |
| 1,726.6 | 10,550.1 | 1,196.4 | 149.4 | -- | 27.5 | 70.6 | 15.1 | |
| 1,322.9 | 18,325.8 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.4 | 5.1 | |
| 2,043.4 | 32,884.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 43.6 | 8.2 | |
| 4,710.6 | 21,538.7 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.2 | 5.4 | |
| 5,216.9 | 8,622.6 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29.4 | 12.4 | |
| 1,036.8 | 9,552.3 | 4,725.6 | 528.7 | 14.9 | 20.7 | 18.7 | 3.2 |
No Review & Analysis are available.
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials,... lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India. Read more
Incorporated
2002
Chairman
--
Managing Director
--
Headquarters
Solan Dist, Himachal Pradesh
Website
Looking for more details about Brooks Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Brooks Laboratories Ltd is ₹55.98 (NSE) and ₹56.48 (BSE) as of 30-Apr-2026 IST. Brooks Laboratories Ltd has given a return of -3.93% in the last 3 years.
The P/E ratio of Brooks Laboratories Ltd is 7.70 times as on 30-Apr-2026, a 74 discount to its peers’ median range of 29.51 times.
The P/B ratio of Brooks Laboratories Ltd is 1.43 times as on 30-Apr-2026, a 69 discount to its peers’ median range of 4.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
3.24
|
|
2024
|
0.00
|
3.71
|
|
2023
|
0.00
|
2.09
|
|
2022
|
0.00
|
2.05
|
|
2021
|
0.00
|
1.94
|
The 52-week high and low of Brooks Laboratories Ltd are Rs 164.02 and Rs 36.30 as of 30-Apr-2026.
Brooks Laboratories Ltd has a market capitalisation of ₹ 166 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Brooks Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.